Preliminary, unaudited ORLADEYO net revenue in the fourth quarter of 2025 was $151 million, +22 percent y-o-y; +36% y-o-y on a comparable basis, excluding European ORLADEYO revenue for the fourth quarter of 2024.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst Raises Price of Key ORLADEYO Treatment
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst’s Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating
- BioCryst price target raised to $32 from $30 at H.C. Wainwright
- BioCryst’s Avoralstat Study: A New Hope for Diabetic Macular Edema?